Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression

Abstract

Understanding of molecular events in cancer requires proteome-level characterisation. Here, proteome profiling of patient samples representing primary and progressed prostate cancer enables the authors to identify pathway alterations that are not reflected at the genomic and transcriptomic levels.